Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Clarus Therapeutics Holdings Inc
Common Shares Outstanding
Clarus Therapeutics Holdings Inc
Common Shares Outstanding Peer Comparison
Competitive Common Shares Outstanding Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
|
Common Shares Outstanding
$21.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Common Shares Outstanding
$2.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Common Shares Outstanding
$2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Pfizer Inc
NYSE:PFE
|
Common Shares Outstanding
$5.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Common Shares Outstanding
$2.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Common Shares Outstanding
$950.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
See Also
What is Clarus Therapeutics Holdings Inc's Common Shares Outstanding?
Common Shares Outstanding
21.7m
USD
Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Common Shares Outstanding amounts to 21.7m USD.
What is Clarus Therapeutics Holdings Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 1Y
0%
Over the last year, the Common Shares Outstanding growth was 0%.